Table 1.
Patient baseline characteristics and demographics (PPS)
| IVT-AFL N = 16 |
|
|---|---|
| Mean age, years | 65.6 (12.9) |
| Male, n (%) | 12 (75.0) |
| Primary diagnosis, n (%) | |
| Proliferative diabetic retinopathy | 10 (62.5) |
| Central retinal vein occlusion | 3 (18.8) |
| Ocular ischemic syndrome | 1 (6.3) |
| Other | 2 (12.5) |
| Duration of disease, days | 60.8 (133.7) |
| Stage of NVG, n (%) | |
| Open angle | 16 (100.0) |
| Closed angle | 0 |
| IOP, mmHg | 34.1 (6.7) |
| NVI grade 3 or 4 (pooled), n (%) | 5 (31.3) |
| NVA grade 3 or 4 (pooled), n (%) | 9 (56.3) |
| Topical IOP-lowering treatment, n (%) | |
| Prostaglandin analogue | 16 (100.0) |
| Sympatholytic agent | 15 (93.8) |
| Carbonic anhydrase inhibitor | 15 (93.8) |
| Sympathomimetic agent | 7 (43.8) |
| Rho kinase inhibitor | 6 (37.5) |
Values are mean (SD) unless otherwise stated
IOP intraocular pressure, IVT-AFL intravitreal aflibercept, NVA neovascularization of the angle, NVG neovascular glaucoma, NVI neovascularization of the iris, PPS per-protocol set, SD standard deviation